Immunotherapy for Type 1 Diabetes: Why Do Current Protocols Not Halt the Underlying Disease Process?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27839907.
- Also identified by DOI 10.1016/j.cmet.2016.10.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T cell-directed immunosuppression only transiently delays the loss of β cell function in recent-onset type 1 diabetes. We argue here that the underlying disease process is carried by innate immune reactivity. Inducing a non-polarized functional state of local innate immunity will support regulatory T cell development and β cell proliferation.
Medical subject headings
- Diabetes Mellitus, Type 1
- Immunotherapy